Uncovering the biology of Chronic Myelomonocytic Leukaemia to identify prognostic and treatment opportunities

Professor John Pimanda

University of New South Wales

$450,000

2025 - 2028

‍

The Research

Chronic myelomonocytic leukemia (CMML) is a neoplasm with impaired blood production. Hypomethylating agents (HMA) are effective in 40-50%, but responses are temporary.

Here, we will apply state-of-the-art techniques that we have developed to explore molecular changes in CMML stem cells using patient samples collected before and during HMA therapy in clinical responders and non-responders to identify critical differences that can be leveraged to develop a prognostic assay and targeted therapies